Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Pancreatic Mucinous Cystic Neoplasms Following GLP-1 Receptor Agonists Use: A Report of Two Cases with Literature Review.

Alsaleh NM, Abo Alshamat R, Almrzouqi W, Alhebshi M, Aljuhani T, Almahdi R, Almaghrabi M, Rammal A, Ageel A, Alzahrani MA

Journal of gastrointestinal cancer29 Jan 2026

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In two middle-aged women without prior pancreatic disease, large distal pancreatic mucinous cystic neoplasms developed following GLP-1 receptor agonist use; causality cannot be established.

    In plain wordsTwo women developed pancreatic cysts after using GLP-1 drugs. The report cannot show that the drugs caused them.

    Outcome
    Not applicablePancreatic mucinous cystic neoplasm after GLP-1 receptor agonist use
    Study

    n = 2

    Outcome group
    Adverse events · Gastrointestinal

    Source sentences

    Summary
    We present two cases of middle-age female patients without prior compline or pancreatic disease who developed large distal pancreatic mucinous cystic neoplasms following GLP-1 Ras use.
    1 context sentence
    Summary · context
    While causality cannot be established, the temporal relationship, absence of alternative etiologies, and supportive literature suggest a possible drug-related effect.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.